OncLive TV

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, India, discusses unmet needs for patients with cervical cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Key opinion leaders share the biggest advancements in oncology made this past year.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Martee L. Hensley, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses Lynch syndrome for patients with endometrial cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.